Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

APLS Apellis Pharmaceuticals

61.760
+2.460+4.15%
Close 09/27 16:00 ET
61.7600.0000.00%
Post Mkt Price 09/27 16:21 ET
High
62.810
Open
60.060
Turnover
63.90M
Low
59.760
Pre Close
59.300
Volume
1.04M
Market Cap
6.79B
P/E(TTM)
Loss
52wk High
70.000
Shares
109.87M
P/E(Static)
Loss
52wk Low
30.171
Float Cap
5.17B
Bid/Ask %
-50.00%
Historical High
73.000
Shs Float
83.66M
Volume Ratio
1.00
Historical Low
11.450
Dividend TTM
--
Div Yield TTM
--
P/B
20.29
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.24%
Amplitude
5.14%
Avg Price
61.653
Lot Size
1
Float Cap
5.17B
Bid/Ask %
-50.00%
Historical High
73.000
Shs Float
83.66M
Volume Ratio
1.00
Historical Low
11.450
Dividend TTM
--
P/B
20.29
Dividend LFY
--
Turnover Ratio
1.24%
Amplitude
5.14%
Avg Price
61.653
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
CEO: Dr. Cedric Francois, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...